88P - Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry

Background

Clinical trials show that NGS can improve cancer care and patient (pt) outcomes by facilitating a molecularly guided treatment approach. Further evidence of the impact of NGS on real-world pts and outcomes, and on the clinical course of different solid tumours, is required.

Methods

We analysed anonymised data (Observation Medical Outcomes Partnership [OMOP] common data model) from the global WAYFIND-R cancer registry (NCT04529122; 3534 pts, recruited 27 Aug 2020–13 Jun 2024) describing real-world treatment decisions after NGS, with standardised data collection. This is the first analysis using the WAYFIND-R Data Sharing and Collaboration Platform.

Results

We analysed 2430 pts with complete cancer diagnosis information; median age was 62 y (range 15–94), 45% were women, 49% were White and 53% were from European countries. The most common cancer type was lung (n = 794), followed by colorectal (332), breast (194), pancreatic (166), ovarian (130), liver (106) and prostate (105); 547 had other cancer types. In pts with information on disease status (n = 1572), 66% of pts had metastatic and 34% had early-stage disease when NGS was performed. In pts with metastatic disease and therapy information (n = 816), 46% had NGS before any therapy, 38% had NGS after first-line therapy and 16% had NGS after two or more lines. Compared with therapies given before NGS, there was an increase in the use of targeted therapy (9% to 21%), cancer immunotherapy (CIT) alone (8% to 16%) and CIT with chemotherapy (15% to 23%) after NGS. When considering tumour types mentioned in the ESMO NGS recommendations, the increase in targeted therapy was particularly noticeable for pts with lung (19% to 32%), ovarian (4% to 22%) and liver cancer (13% to 26%). For other tumour types, the increase in targeted therapy, CIT alone and CIT with chemotherapy was 10% to 19%, 12% to 22% and 8% to 17%, respectively.

Conclusions

These data describe the real-world use of NGS and how it impacts treatment decisions in routine care by increasing the use of targeted therapy and CIT in several cancer types across the globe. Data from the WAYFIND-R registry will allow further real-world studies through the WAYFIND-R platform research environment.

Clinical trial identification

NCT04529122, first posted 27 August 2020.

Editorial acknowledgement

Research support in the form of third-party medical writing assistance for this abstract, furnished by Katie Wilson, PhD, of Nucleus Global (an Inizio company), was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

C. Le Tourneau: Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Personal, Other, Travel: MSD, BMS, AstraZeneca; Financial Interests, Personal, Other, Honoraria: BMS, MSD, Merck Serono, Roche, Nanobiotix, GSK, Ratuken, Seattle Genetics, AstraZeneca; Non-Financial Interests, Personal, Advisory Role: BMS, MSD, Merck Serono, Roche, Nanobiotix, GSK; Non-Financial Interests, Personal, Advisory Board: Seattle Genetics, AstraZeneca, Rakuten; Non-Financial Interests, Personal, Other, Research funding in the form of third-party medical writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. R. Dienstmann: Financial Interests, Personal, Full or part-time Employment: Oncoclínicas; Financial Interests, Personal, Ownership Interest: Trialing; Financial Interests, Institutional, Research Grant: Merck; Non-Financial Interests, Personal, Advisory Role: Roche, Boehringer Ingelheim; Financial Interests, Personal, Speaker’s Bureau: Roche, Ipsen, Sanofi, MSD oncology, Servier, Amgen, Libbs; Non-Financial Interests, Personal, Other, Research funding in the form of third-party medical writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffman-La Roche Ltd. A. Hackshaw: Financial Interests, Personal, Advisory Board, AH is an investigator for an academic study (SUMMIT) sponsored by UCL that is funded by GRAIL, Inc.; has received one honorarium for an advisory board meeting for GRAIL, Inc; received a consulting fee from Evidera Inc (for one GRAIL-initiated project).: GRAIL Inc; Financial Interests, Personal, Other, For delivering general education/training in clinical trials.: AbbVie, Boehringer Ingelheim, Clovis, Ipsen, Takeda, AstraZeneca, Daiichi Sankyo, Merck Serono, MSD, UCB, Kyowa Kirin, Servier, Sobi, Pfizer, Roche; Financial Interests, Personal, Stocks/Shares, Shares were sold in 2020: Illumina, Thermo Fisher; Financial Interests, Institutional, Research Grant, Grant for a UCL-academic sponsored clinical trial: Roche, MSD, Autolus, AstraZeneca, Boehringer Ingelheim, GRAIL Inc, Takeda, Pfizer, Novartis, Bristol Myers Squibb, Janssen; Non-Financial Interests, Principal Investigator, Co-lead academic investigator for an observational study sponsored and conducted by Roche. Unpaid/no honoraria for this role.: Roche; Non-Financial Interests, Advisory Role, AH is on the scientific advisory board for Adela Bio and receives no payments/honoraria for this but has share options available.: Adela Bio; Non-Financial Interests, Advisory Role, Unpaid member of advisory board: Navio. J. Geissler: Financial Interests, Institutional, Research Grant: Novartis, Incyte, Bristol Myers Squibb, Pfizer, Takeda; Financial Interests, Personal, Other, Travel: Amgen, Alnylam, BioMarin, Novartis, Pfizer, Roche, Servier, UCB; Non-Financial Interests, Personal, Advisory Role: Alnylam, Bayer, Boehringer Ingelheim, BioMarin, Daiichi Sankyo, Gilead, Janssen, Novartis, Pfizer, Roche, Servier, Sanofi, Sobi, UCB; Non-Financial Interests, Personal, Other, Research funding in the form of third-party medical writing assistance from F. Hoffmann-La Roche Ltd: F.Hoffman-La Roche Ltd. A. Ferro: Financial Interests, Personal, Full or part-time Employment: Roche products limited; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd; Non-Financial Interests, Personal, Other, Research funding in the form of third-party medical writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. E. Cheese: Financial Interests, Personal, Full or part-time Employment: Roche products limited; Financial Interests, Personal, Stocks/Shares: IQVIA; Non-Financial Interests, Personal, Other, Research funding in the form of third-party medical writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. E. Schirghuber: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd; Non-Financial Interests, Personal, Other, Research funding in the form of third-party medical writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. J. Blay: Financial Interests, Institutional, Research Grant: Novartis, Bayer, GSK, Pfizer, Deciphera, Roche, BMS, MSD, AstraZeneca; Financial Interests, Personal, Other, Leadership role: Innate Pharma; Financial Interests, Personal, Other, Honoraria: Novartis, Bayer, Pfizer, Deciphera, Roche; Financial Interests, Personal, Advisory Role: Novartis, Bayer, GSK, Pfizer, Deciphera, Roche, BMS, MSD, AstraZeneca; Non-Financial Interests, Personal, Other, Research funding in the form of third-party medical writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd.